Septerna (NASDAQ:SEPN) Reaches New 1-Year Low – Here’s Why

by · The Cerbat Gem

Septerna, Inc. (NASDAQ:SEPN – Get Free Report) shares hit a new 52-week low during trading on Wednesday . The stock traded as low as $4.17 and last traded at $6.87, with a volume of 8617193 shares. The stock had previously closed at $12.96.

Analyst Upgrades and Downgrades

Several research analysts have recently issued reports on SEPN shares. Cantor Fitzgerald reissued an “overweight” rating and issued a $50.00 target price on shares of Septerna in a research report on Tuesday, February 11th. TD Cowen initiated coverage on shares of Septerna in a research report on Tuesday, November 19th. They set a “buy” rating for the company. Wells Fargo & Company cut Septerna from an “overweight” rating to an “equal weight” rating and dropped their price target for the stock from $43.00 to $14.00 in a research report on Tuesday. Finally, JPMorgan Chase & Co. assumed coverage on Septerna in a research note on Tuesday, November 19th. They issued an “overweight” rating and a $38.00 target price on the stock.

View Our Latest Stock Report on SEPN

Septerna Stock Up 6.1 %

The stock has a fifty day moving average price of $18.11.

Hedge Funds Weigh In On Septerna

Several hedge funds and other institutional investors have recently modified their holdings of the company. Woodline Partners LP purchased a new position in Septerna in the fourth quarter worth about $6,870,000. Zimmer Partners LP purchased a new stake in Septerna during the fourth quarter valued at approximately $229,000. Soleus Capital Management L.P. purchased a new position in shares of Septerna during the 4th quarter worth $15,467,000. Nuveen Asset Management LLC bought a new stake in shares of Septerna during the 4th quarter valued at $549,000. Finally, OCONNOR A Distinct Business Unit of UBS ASSET MANAGEMENT AMERICAS LLC bought a new position in Septerna in the 4th quarter worth $278,000.

Septerna Company Profile

(Get Free Report)

We are a clinical-stage biotechnology company pioneering a new era of G protein-coupled receptor (GPCR) oral small molecule drug discovery powered by our proprietary Native Complex Platform™. Our industrial-scale platform aims to unlock the full potential of GPCR therapies and has led to the discovery and development of our deep pipeline of product candidates focused initially on treating patients in three therapeutic areas: endocrinology, immunology and inflammation, and metabolic diseases.

See Also